Home
Search
Study Topics
Glossary
|
|
|
|
|
Tracking Information | |||||||||
---|---|---|---|---|---|---|---|---|---|
First Received Date † | September 13, 2005 | ||||||||
Last Updated Date | April 29, 2009 | ||||||||
Start Date † | September 2004 | ||||||||
Current Primary Outcome Measures † |
Children's Psychiatric Rating Scale [ Time Frame: Measured monthly throughout the study ] [ Designated as safety issue: No ] | ||||||||
Original Primary Outcome Measures † | Same as current | ||||||||
Change History | Complete list of historical versions of study NCT00183404 on ClinicalTrials.gov Archive Site | ||||||||
Current Secondary Outcome Measures † |
|
||||||||
Original Secondary Outcome Measures † |
|
||||||||
Descriptive Information | |||||||||
Brief Title † | Long-Term Olanzapine Treatment in Children With Autism | ||||||||
Official Title † | Long-Term Olanzapine Treatment in Children With Autism | ||||||||
Brief Summary | This study will determine the short- and long-term safety and effectiveness of the drug olanzapine (Zyprexa®) for reducing symptoms of autism in children. |
||||||||
Detailed Description | Autism is a serious childhood disorder that can significantly impair functioning and development. Educational and psychosocial programs are standard treatments for autistic children, but drug therapy is often needed as well. Haloperidol is the drug most commonly prescribed for symptoms of autism. However, long-term administration of haloperidol has been associated with adverse effects such as blurred vision, constipation, and nausea. The investigation of alternative drug treatments is necessary. This study will determine whether the antipsychotic drug olanzapine may be a safe and effective alternative to haloperidol for treating symptoms of autism in children. This study will last 36 weeks and will comprise 2 phases. In Phase I, participants will be randomly assigned to receive either olanzapine or placebo for 12 weeks. Participants who do not respond to treatment will complete their participation in the study. Participants who respond to their assigned Phase I treatment will continue onto Phase II. All Phase II participants will receive olanzapine daily for 6 months. Self-report scales and checklists will be used to assess participants after each phase; these measures will be completed by participants and their parents. |
||||||||
Study Phase | Phase II, Phase III | ||||||||
Study Type † | Interventional | ||||||||
Study Design † | Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study | ||||||||
Condition † | Autism | ||||||||
Intervention † | Drug: Olanzapine | ||||||||
Study Arms / Comparison Groups | Other: Participants will take open olanzapine for up to 20 additional weeks after phase 1. | ||||||||
Publications * | |||||||||
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|||||||||
Recruitment Information | |||||||||
Recruitment Status † | Recruiting | ||||||||
Estimated Enrollment † | 40 | ||||||||
Estimated Completion Date | October 2009 | ||||||||
Estimated Primary Completion Date | July 2009 (final data collection date for primary outcome measure) | ||||||||
Eligibility Criteria † | Inclusion Criteria:
Exclusion Criteria:
|
||||||||
Gender | Both | ||||||||
Ages | 3 Years to 12 Years | ||||||||
Accepts Healthy Volunteers | No | ||||||||
Contacts †† |
|
||||||||
Location Countries † | United States | ||||||||
Expanded Access Status | |||||||||
Administrative Information | |||||||||
NCT ID † | NCT00183404 | ||||||||
Responsible Party | Richard P. Malone, MD, Drexel University College of Medicine | ||||||||
Secondary IDs †† | DDTR B2-NDA | ||||||||
Study Sponsor † | National Institute of Mental Health (NIMH) | ||||||||
Collaborators †† | |||||||||
Investigators † |
|
||||||||
Information Provided By | National Institute of Mental Health (NIMH) | ||||||||
Verification Date | April 2009 | ||||||||
† Required WHO trial registration data element. †† WHO trial registration data element that is required only if it exists. |